Sanjay Bambhaniya · May 19, 2026

Q-Line Biotech SME IPO Review | APPLY or AVOID?

SME Book Build Listed

Healthcare

NSE SME

Price Band

₹326 - ₹343

Issue Size

₹214.48 Cr

Lot Size

400 shares

Min. Investment

₹1,37,200

Live GMP ₹117

34.11% Est. Listing: ₹460

SIP Calc Compare

IPO Timeline

DRHP FILED —

OPEN May 21, 2026

CLOSE May 25, 2026

ALLOTMENT May 26, 2026

LISTING May 29, 2026

IPO DETAILS REVIEW GMP SUBSCRIPTION ALLOTMENT STATUS

Q-Line Biotech Ltd. started in 2010. It operates in the Healthcare industry and provides diagnostic reagents to its customers across India. This business is based in Lucknow. This IPO review covers the main facts of the offer. It helps you decide if the issue fits your portfolio.
Q-Line Biotech Ltd. shows rapid growth, but the sustainability of sudden margins remains a key point for investors to consider investors. The massive profit jump in a short pre-IPO period raises serious quality questions within a fragmented diagnostics industry.

✅ Strengths

Impressive operational revenue compound growth
Four distinct domestic production units
Dedicated internal research development laboratory
Strong pan India distribution network
Experienced core promoter team expertise
Explicit allocation reducing existing debt
Highly diversified diagnostics product catalog
Expanding core operational business efficiencies

⚠️ Challenges

Heavy corporate debt balance constraints
Historical bottom line net profit fluctuations
Sudden recent pre IPO profitability spike
Heavy raw material supplier reliance
Steep retail minimum investment barrier
Lower platform trading liquidity risks
Fierce fragmented market price competition
Future medical regulatory shifts uncertainty

Financial Update

The company released its restated financial statements for the year ending March 31, 2025. Total revenue was ₹322.58 crore increased from ₹206.45 in previous year. The net profit for the same period was ₹28.13 crore decreased from ₹34.44 in previous year. The business recorded a net profit of ₹32.10 crore on a total income of ₹184.81 crore during FY23. The total income rose to ₹322.58 crore in FY25 but accounting adjustments dragged down the profits. The latest nine month period ending December 31, 2025 brought a bumper net profit of ₹38.69 crore. This sudden spike right before the public issue creates doubt about stable future returns. This trend should be carefully studied prior to any investment.

IPO Valuation

The upper price band is ₹343. This price leads to a Price-to-Earnings (P/E) ratio of 28.44. The average P/E for the industry is 19.23. The asking price shows a P/E ratio of 15.51 if we calculate it using the annualized nine month earnings of FY26. The company wants a total market cap of ₹800.16 crore at the final upper price limit. The price to book value ratio sits at 2.44 based on the net asset value of ₹140.81 per share. The management did not provide any post IPO net asset value data points in their official offer prospectus.

IPO Objective

The company will use the proceeds of the offer to meet stated objectives:

The company wants funds for business working capital.
They will spend for paying back old company bank loans.
The remaining fresh money will support regular administrative corporate expenses.

Promoters & Lead Manager

Saurabh Garg leads corporate management decisions with deep domain sales expertise. The promoters have over 30 years of domain expertise in the diagnostic industry.
Hem Securities Ltd and Share India Capital Services Pvt Ltd jointly manage this issue.
The two associate merchant bankers handled 79 public issues during the past three years.
Eight historical public issues managed by these firms closed below the issue price on listing date.
Purva Sharegistry India Pvt Ltd is working as the official registrar for this issue.

Peer Comparison

Below is the comparison of the company with its listed peers using data from May 21, 2026. The management stated in the prospectus that there are no listed peers for comparison. The internal valuation table mentions an industry average benchmark P/E of 19.23. Investors have no direct listed companies to evaluate the actual financial relative performance. This lack of clear industry peers makes the comparison column blank.

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	RoNW (%)	P/BV Ratio

Financial data sourced from annual reports and stock exchange data, using restated financial statements for 2024-25. NAV per share (closing net worth divided by weighted average number of paid-up equity shares) and RoNW (net profit after tax divided by closing net worth).

IPO Review & Analyst Rating

The company develops and manufactures a diverse range of reagents and consumables. It supplies diagnostic equipment and in-vitro diagnostics products directly or through distributors to hospitals and labs. The business has 362 permanent payroll employees and 223 contract employees. The financial performance shows growing top lines but an inconsistent bottom line due to an extraordinary loss of ₹16.97 crore in FY25. The company carries large borrowings of ₹242.57 crore and high contingent liabilities of ₹61.64 crore.

Analyst Name	Recommendation
Angel One	Neutral / Cautious
ICICI Direct	Not Rated (Structural Play)

Disclaimer: The information on the site is informational only. The contents of this blog are not financial advice. You should not invest in any stock market instrument without consulting your Financial advisor.

Sanjay Bambhaniya

Sanjay has 8+ years of experience in data-driven IPO insights. His expertise in digital marketing and web development complements his financial knowledge and helps him to develop effective fintech solutions. He is an entrepreneur and director who helps investors understand complex primary market trends in easy-to-understand IPO reports, news, and updates.

Discussion & Feedback

0 Comments

No comments yet. Be the first to share your thoughts!